Data / Drug companies / Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc.: 65 products in the FDA NDC directory, labeler code 50419
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Bayer HealthCare Pharmaceuticals Inc. (labeler code 50419) lists 65 products in the FDA National Drug Code Directory, covering 24 finished drugs by generic name. By type: 64 prescription drugs, 1 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on June 12, 2026.
The request: Watch Bayer HealthCare Pharmaceuticals Inc. (FDA labeler code 50419): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 50419
- Products in commercial distribution
- 65
- Packages
- 152
- Finished drugs by generic name
- 24
- Prescription products
- 64
- Over the counter products
- 0
- Flagged as original packager
- 57 of 57 products that carry the flag
- Started marketing in the last 12 months
- 12
- Earliest marketing start
- October 22, 1987
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 63 | 96.9% |
| Drugs for further processing | 1 | 1.5% |
| Biologics (BLA) | 1 | 1.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 64 | 98.5% |
| Drugs for further processing | 1 | 1.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Gadoquatrane | 11 | 1 |
| Estradiol | 7 | 53 |
| Riociguat | 5 | 2 |
| Iopromide | 4 | 1 |
| Larotrectinib | 4 | 2 |
| Gadobutrol | 3 | 6 |
| Finerenone | 3 | 1 |
| Levonorgestrel | 3 | 31 |
| Drospirenone and ethinyl estradiol | 2 | 16 |
| Drospirenone and estradiol | 2 | 1 |
| Sorafenib | 2 | 8 |
| Ciprofloxacin | 2 | 41 |
| Nifurtimox | 2 | 1 |
| Ciprofloxacin hydrochloride | 2 | 36 |
| Darolutamide | 1 | 1 |
| Interferon beta-1b | 1 | 1 |
| Gadoxetate disodium | 1 | 1 |
| Estradiol and levonorgestrel | 1 | 1 |
| Praziquantel | 1 | 2 |
| Estradiol valerate and estradiol valerate/dienogest | 1 | 2 |
| Elinzanetant | 1 | 1 |
| Radium ra 223 dichloride | 1 | 1 |
| Sevabertinib | 1 | 1 |
| Regorafenib | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 19 | 29.2% |
| Tablet, film coated | 19 | 29.2% |
| Kit | 8 | 12.3% |
| Patch | 8 | 12.3% |
| Capsule | 3 | 4.6% |
| Intrauterine device | 3 | 4.6% |
| Tablet | 2 | 3.1% |
| Solution, concentrate | 2 | 3.1% |
| Injection, solution | 1 | 1.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Estrogen | 10 |
| Kinase Inhibitor | 7 |
| Progestin | 6 |
| Soluble Guanylate Cyclase Stimulator | 5 |
| Gadolinium-based Contrast Agent | 4 |
| Radiographic Contrast Agent | 4 |
| Progestin-containing Intrauterine System | 4 |
| Nonsteroidal Mineralocorticoid-Receptor Antagonist | 3 |
| Fluoroquinolone Antibacterial | 2 |
| Anthelmintic | 1 |
| Radioactive alpha-Particle Emitting Therapeutic Agent | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Ambelvist | 50419-332 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-331 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-330 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-329 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-328 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-327 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-326 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-324 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-323 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-322 | Injection | New drug applications (NDA) | June 12, 2026 |
| Ambelvist | 50419-321 | Injection | New drug applications (NDA) | June 12, 2026 |
| Hyrnuo | 50419-397 | Tablet, film coated | New drug applications (NDA) | November 19, 2025 |
| Lynkuet | 50419-475 | Capsule | New drug applications (NDA) | October 24, 2025 |
| Finerenone | 50419-542 | Tablet | Drugs for further processing | July 13, 2025 |
| Nexavar | 50419-489 | Tablet, film coated | New drug applications (NDA) | October 2, 2023 |
| Vitrakvi | 50419-393 | Solution, concentrate | New drug applications (NDA) | December 6, 2022 |
| Ultravist | 50419-348 | Injection | New drug applications (NDA) | June 8, 2022 |
| Ultravist | 50419-347 | Injection | New drug applications (NDA) | June 8, 2022 |
| Kerendia | 50419-542 | Tablet | New drug applications (NDA) | July 9, 2021 |
| Kerendia | 50419-541 | Tablet, film coated | New drug applications (NDA) | July 9, 2021 |
| Kerendia | 50419-540 | Tablet, film coated | New drug applications (NDA) | July 9, 2021 |
| Lampit | 50419-751 | Tablet, film coated | New drug applications (NDA) | October 1, 2020 |
| Lampit | 50419-750 | Tablet, film coated | New drug applications (NDA) | October 1, 2020 |
| Nubeqa | 50419-395 | Tablet, film coated | New drug applications (NDA) | July 31, 2019 |
| Vitrakvi | 50419-392 | Solution, concentrate | New drug applications (NDA) | July 26, 2019 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.